Drugs / IBC-Ab002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05551741 | Feb 2023 → Dec 2025 | Alzheimer disease | Immunobrain Checkpoint | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBC-Ab002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05551741 ↗ |
| Action | Inhibit | “Preclinical studies using rodent models showed that transient systemic blockade of programmed death-ligand 1 is associated with reduced neuroinflammation, neuroprotection and...” PMID 42458012 ↗ Jul 2026 |
| Modality | Monoclonal antibody | “An anti-PD-L1 monoclonal antibody” NCT05551741 ↗ |
| Route | Intravenous | “escalating multiple intravenous (IV) doses of IBC-Ab002” NCT05551741 ↗ |